Clostridium botulinum

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Clostridium botulinum
DrugBank Accession Number
DB14223
Background

Not Available

Type
Biotech
Groups
Experimental
Synonyms
  • Bacillus botulinus whole
  • Bacillus putrificus whole
  • Botulobacillus botulinus whole
  • Clostridium botulinum whole
  • Clostridium putrificum whole
  • Ermengemillus botulinus whole
  • Pacinia putrifica whole

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofAnkle spasticity following a stroke or traumatic brain injury••••••••••••••••••••••••••• ••••••• ••• ••••••••
Symptomatic treatment ofAxillary hyperhidrosis••••••••••••••••••••••••••• ••••••• ••• ••••••••
Symptomatic treatment ofBlepharospasm••••••••••••••••••••••••••• ••••••• ••• ••••••••
Symptomatic treatment ofCervical dystonia••••••••••••••••••••••••••• ••••••• ••• ••••••••
Symptomatic treatment ofEquinus foot deformity in children with cerebral palsy•••••••••••••••••••••• ••••••• ••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ProtoxinGel10 g/10mLTopicalProtox Inc.2016-11-10Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ProtoxinClostridium botulinum (10 g/10mL)GelTopicalProtox Inc.2016-11-10Not applicableUS flag

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
0296055VE0
CAS number
Not Available

References

General References
Not Available
RxNav
1811178
Wikipedia
Clostridium_botulinum

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4TerminatedTreatmentScarring1
3Active Not RecruitingTreatmentGlabellar Frown Lines (GL)1
3CompletedTreatmentElectromyography / ElectroPhys: Myopathy / EMG Syndrome / EMG: Myopathy / Pelvic Floor Disorders / Pelvic Pain / Pelvic Pain Syndrome1
3CompletedTreatmentGlabellar Frown Lines (GL)2
3CompletedTreatmentModerate to Severe Glabellar Frown Lines1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntramuscular
Injection, powder, for solutionIntramuscular125 SU
Injection, powder, for solutionParenteral100 Einheiten
Injection, powder, for solutionParenteral4 Einheiten/0.1ml
Injection, powder, for solutionParenteral50 Einheiten
Injection, powder, for solutionParenteral100 U
Injection, powder, for solutionParenteral
Injection, powder, for solutionParenteral200 U
Injection, powder, for solutionParenteral50 U
Injection, powder, for solutionParenteral500 Einheiten
Injection, powder, for solutionIntramuscular; Subcutaneous300 u/vial
Injection, powder, for solutionIntramuscular; Subcutaneous500 U/vial
Injection, powder, lyophilized, for solutionIntramuscular100 Units
GelTopical10 g/10mL
Injection, powder, for solutionParenteral0.1 ml
Injection, powder, for solutionParenteral200 Einheiten
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at July 04, 2018 22:46 / Updated at February 13, 2021 10:53